Trial Profile
A Phase I/IIA, Non-Randomized, Open Label, Single Dose, Dose-Escalation, Safety Study of BKT140, a CXCR4 Antagonist in Patients With Multiple Myeloma.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Motixafortide (Primary)
- Indications Multiple myeloma; Stem cell mobilisation
- Focus Adverse reactions; Therapeutic Use
- Sponsors Biokine Therapeutics
- 19 Apr 2016 Results published as per BioLineRx Ltd media release.
- 01 Jul 2010 Status changed from recruiting to completed, according to ClinicalTrials.gov
- 03 Jun 2009 Promising results have been observed in patients with multiple myeloma, as reported in a Biokine Therapeutics media release.